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The benefits of implementing high throughput sequencing in the clinic are quickly becoming apparent. However, few
freely available bioinformatics pipelines have been built from the ground up with clinical genomics in mind. Here we
present Cpipe, a pipeline designed specifically for clinical genetic disease diagnostics. Cpipe was developed by the
Melbourne Genomics Health Alliance, an Australian initiative to promote common approaches to genomics across
healthcare institutions. As such, Cpipe has been designed to provide fast, effective and reproducible analysis, while also
being highly flexible and customisable to meet the individual needs of diverse clinical settings. Cpipe is being shared
with the clinical sequencing community as an open source project and is available at http://cpipeline.org.Background
Diagnostic laboratories are rapidly adopting high through-
put genomic sequencing for clinical genetic tests. This
transition is enabling a dramatic expansion in our ability
to diagnose and screen heterogeneous monogenic disor-
ders [1]. One critical aspect of a clinical genomics test is
the bioinformatics pipeline used to analyse the sequencing
data and output variants for clinical consideration. Thus
far most clinical sequencing analysis pipelines have been
driven by individual laboratories, who have either devel-
oped their own bioinformatics capability for processing
data, relied on commercial products or have partnered
with research institutions to acquire the expertise needed.
This approach has enabled rapid adoption, but has re-
sulted in a wide diversity of implementation approaches
and great variability in the methods used for evaluation,
interpretation and reporting of variants. When pipelines
have been primarily developed for research use they often
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required in the clinical diagnostic setting. Additionally,
many such analysis pipelines are designed without
prioritising the ability to generalise to different diseases,
technologies or computational contexts. Commercial
pipelines can address some of these problems. However
they are inevitably constrained in the level of custom-
isation and transparency they can offer due to their
commercial nature. Additionally commercial pipelines
can be expensive for laboratories to acquire, evaluate
and deploy. Altogether these issues impede the stand-
ardisation of bioinformatics pipelines for routine diag-
nostics across multiple clinics and healthcare systems.
An analysis pipeline that is specifically designed for the
clinical setting and that can be informed and iteratively
improved by the clinical diagnostic community has the
potential to offer the most effective diagnostic value.
Recognising these issues, the Melbourne Genomics
Health Alliance was formed as a collaboration between
seven institutions, including hospitals, diagnostic labora-
tories, universities and research institutes, with the aim
of developing a common approach to the analysis and
management of genomic data within Australia’s publicly
funded healthcare system. A key outcome of the Alliance
has been the development of a consensus bioinformatics
pipeline, which we have called Cpipe. Cpipe is foundedarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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) applies to the data made available in this article, unless otherwise stated.
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ging in the global clinical sequencing community and
are already being employed by many of the members of
the Alliance. However, the goal of Cpipe is not to im-
prove upon these core bioinformatics analysis methods,
nor is it ultimately to focus on any particular tool set.
Rather, the aim of Cpipe is to create a common frame-
work for applying the tools that can be readily adapted
for a diverse range of diagnostic settings and clinical
indications.
We identified three key requirements for a clinical bio-
informatics pipeline that differ from a pipeline intended
for research use. First, a clinical pipeline must be de-
signed with a greater emphasis on robust and reprodu-
cible analysis. There must be clear records of what
analysis was performed and what files were used to gen-
erate results. Second, a number of specialised bioinfor-
matics steps are required in clinical settings. For
example, one key difference in a clinical setting is the
need for variants to be assessed for their relevance to a
given patient. Therefore it becomes vital to filter and pri-
oritise variants to speed up this process and thus reduce
the time clinicians spend assessing variants. Finally, the
pipeline must be highly transparent and modular, so that
the individual steps as well as the overall flow of the
pipeline are easy to understand and modify. These qual-
ities are critical in the clinical environment to allow la-
boratories to maintain and adapt pipelines to their needs
without compromising on quality.
There have been a number of previous efforts to create
publicly available analysis pipelines for high throughput
sequencing data. Examples include Omics-Pipe [2],
bcbio-nextgen [3], TREVA [4] and NGSane [5]. These
pipelines offer a comprehensive, automated process that
can analyse raw sequencing reads and produce anno-
tated variant calls. However, the main audience for these
pipelines is the research community. Consequently,
there are many features required by clinical pipelines
that these examples do not fully address. Other groups
have focused on improving specific features of clinical
pipelines. The Churchill pipeline [6] uses specialised
techniques to achieve high performance, while maintain-
ing reproducibility and accuracy. However it is not freely
available to clinical centres and it does not try to im-
prove broader clinical aspects such as detailed quality
assurance reports, robustness, reports and specialised
variant filtering. The Mercury pipeline [7] offers a com-
prehensive system that addresses many clinical needs: it
uses an automated workflow system (Valence, [8]) to en-
sure robustness, abstract computational resources and
simplify customisation of the pipeline. Mercury also in-
cludes detailed coverage reports provided by ExCID [9],
and supports compliance with US privacy laws (HIPAA)
when run on DNANexus, a cloud computing platformspecialised for biomedical users. Mercury offers a com-
prehensive solution for clinical users, however it does
not achieve our desired level of transparency, modularity
and simplicity in the pipeline specification and design.
Further, Mercury does not perform specialised variant
filtering and prioritisation that is specifically tuned to
the needs of clinical users.
Cpipe focuses on implementing or improving the three
key aspects of clinical analysis pipelines that we have
identified. The first aspect includes features that support
the robustness and quality of the pipeline operation and
these are provided automatically in Cpipe by the under-
lying pipeline framework, Bpipe [10]. The second aspect
is the addition of specialised bioinformatics steps that
are required for clinical settings. These include detailed
quality reports, additional filtering and prioritisation of
variants, and carefully designed output formats that ac-
celerate clinical interpretation. Finally, Cpipe aims to be
highly transparent and modular, so that it is easy to
understand and modify the underlying tools used. This
is critical to ensuring that Cpipe can be deployed in di-
verse clinical settings and can be updated and shared be-
tween different organisations, while still maintaining a
common underlying framework.
Cpipe has been developed in close consultation with
many different stakeholders from the clinical and re-
search sequencing community in Melbourne, Australia.
It is being actively used by three separate institutions for
clinical sequencing, and is undergoing accreditation for
diagnostic use. By adopting Cpipe, a solution that has
already been tested in a diagnostic context, a laboratory
can save significant effort in developing a pipeline. Per-
haps even more importantly, by adopting Cpipe they can
become part of a community of users and developers,
and can benefit from the ongoing maintenance and ac-
tive development that will occur over time. The open
source license of Cpipe (GPLv3) will allow users of
Cpipe to become contributors to the project, further en-
suring its ongoing maintenance and development.
Implementation
Cpipe is built using Bpipe
Cpipe is implemented using a pipeline construction
framework called Bpipe [10]. Bpipe automatically pro-
vides many features supporting our goals in creating
Cpipe. Bpipe and its features are central to our imple-
mentation. Therefore we named the pipeline Cpipe,
emphasising the close relationship between the two, and
with the ‘C’ indicating the clinical nature of the pipeline.
One of the most notable features of Bpipe is its pipe-
line construction language, which allows commands to
be specified in a form that is nearly identical to execut-
ing them manually. This greatly increases the accessibil-
ity of Bpipe pipelines, as users do not need to learn a
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to understand existing pipelines or to make simple mod-
ifications. Another powerful feature of Bpipe is that it
automatically adds robustness features to every com-
mand executed with minimal intervention from the user.
These features include automatic tracking of command
history, logging of input and output files, clean-up of
partially created files from failed commands, dependency
tracking, automatic removal of intermediate results, gen-
eration of graphical reports, tracking of performance sta-
tistics, and notifications by email and instant messaging
in response to failures. The audit trail created by this
process can be used to reproduce or verify any part of
any previous analysis.
Another key feature that Bpipe offers is abstraction
from the computational environment. That is, Bpipe en-
ables the same pipeline to easily work on a computa-
tional cluster, a local server or even a stand-alone
desktop computer. This feature is important for building
a pipeline that can be deployed in many different environ-
ments. To facilitate maximum utilisation of resources,
Bpipe supports parallelisation, so that independent steps
can be run simultaneously with minimal effort from the
user. These features enable Cpipe to utilise cluster infra-
structure where available, but importantly, Cpipe can
automatically adapt to environments where significant
parallelisation is not an option. Cpipe parallelises by first
aligning reads from each lane and sample in parallel. After
the initial alignment, processing is parallelised only by
sample, and by parallelising selected independent opera-
tions at the sample level.
Generation of reports and evidence about the oper-
ation of the pipeline is a key requirement in clinical set-
tings. Bpipe offers built in template-driven report
generation features. These operational reports can be
easily and automatically attached to emails that are sent
in response to events that occur as part of the analysis.
This makes it possible for operators to be alerted by
email when pipeline errors or QC issues occur. A final
important aspect of Bpipe is the high-level job manage-
ment capabilities. Bpipe gives the operator the ability to
start a pipeline with a single command, and to easily
stop or view the status of running pipelines.
Cpipe architecture
Analysis profiles
At the root of Cpipe’s architecture is the assumption
that, in a clinical diagnostic setting, sequencing runs will
be performed on many different patients, each of whom
may have a different disease. These different diseases
may require not only differing genes to be prioritised,
but also different settings or tools to be applied in the
analysis pipeline. As the field matures, it is even likely
that patients with the same disease will be prescribedpersonalised diagnostic tests based on their individual
phenotypes. However, this variability presents challenges,
because most pipelines use a single set of targeted genes
and tool settings for all samples in the analysis. To
address this problem, Cpipe defines the concept of an
‘analysis profile’. The analysis profile is predefined to op-
timise settings for a particular subgroup of patients, such
as those with a common clinical diagnosis. A specific
analysis profile is assigned to each sample as an input to
the pipeline. The parameters defined in the analysis pro-
file can include: the list of genes to be included or ex-
cluded in the analysis; minimum quality and coverage
thresholds for variants that are reported; the width of
the window beyond exonic boundaries that should be
used to identify potential splice site variants; and any
other customisable settings that could be applicable to
different patients. Cpipe supports definition of new cus-
tomisable settings in a simple manner via a text file that
can be supplied as part of the analysis profile definition
for each sample. By using fixed, predefined, analysis pro-
files, laboratories can validate and accredit each profile
independently as the need arises. This strikes a balance
between customisation for each sample and the needs of
accreditation agencies to have tests validated in advance.
In the context of the Melbourne Genomics Health Alliance,
the same exome capture platform was used for every pa-
tient but distinct gene sets were reported depending on the
phenotype of the patient.
Directory structure
Cpipe defines a standard directory structure that is used
for all analyses. This predefined structure has two im-
portant benefits. First, it enhances maintainability and
usability of the pipeline. Second, it ensures that oper-
ational parts of the pipeline are well separated from
parts of the pipeline that should not be modified. For
each analysis, all the inputs, outputs and design files are
isolated in a single ‘batch’ folder so that each batch is
completely isolated from other batches (Fig. 1). When
an analysis runs for the first time, all of the files that are
defined in the analysis profile are copied to a dedicated
‘design’ folder so that if the analysis is re-executed in the
future, the same results will be produced. These factors
help to ensure the reproducibility of results.
Bioinformatics analysis process
The core bioinformatic analysis implemented by Cpipe
(Fig. 2) is based on the approach developed and recom-
mended by the Broad Institute [11], and generally
accepted by the community as best practice. This work-
flow includes: alignment using BWA mem [12], dupli-
cate removal using Picard MarkDuplicates [13], Indel
realignment using the GATK IndelRealigner, base quality
score recalibration using the GATK BaseRecalibrator
Fig. 1 Batch directory structure used by Cpipe. Each analysis is conducted using a standardised directory structure that separates raw data,
design files and generated results from each other. All computed results of the analysis are confined to the ‘analysis’ directory, while source data
is kept quarantined in the ‘data’ directory. The analysis directory keeps separate directories for each stage of the analysis starting with initial
quality control (fastqc), alignment (align), variant calling (variants) and final quality control (qc). The final analysis results are placed in the
‘results’ directory
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The Broad Institute guidelines were developed for use in
a research setting, and thus require some modifications
for use in a clinical setting. Modifications in Cpipe in-
clude: (1) using Annovar [14] for annotation of variants
as this tool provided a more comprehensive set of anno-
tations desired by the clinical users in the Melbourne
Genomics Health Alliance; (2) calling variants in each
sample separately instead of using joint calling, as this
ensures that results for a sample can be reproduced
without requiring data belonging to other samples; (3)
no variant quality score recalibration is performed be-
cause variant quality scores themselves are not used in
downstream filtering by Cpipe, and because unless a
large independent reference sample set is created, the
procedure causes inter-sample dependencies.
The analysis process described in this section makes
use of two components (GATK and Annovar) that may
require a license for clinical use. To allow use of the
pipeline without licensing these components, Cpipe
supports alternative options. To substitute for GATK,
Cpipe allows use of an older version of GATK that is
free to use commercially. The Variant Effect Predictor
and SnpEFF [15] are supported as alternative options to
Annovar that are free for commercial and clinical use.The default pipeline that Cpipe implements is de-
signed as a sound baseline that caters to a broad set of
clinical needs. However it is fully intended that labora-
tories will tune these components and potentially re-
place them with different tools that may be better suited
to a particular application. The current default Cpipe
workflow is intended for analysis of single, unrelated
samples. Analysis of related samples requires joint call-
ing within each family to provide fully informative re-
sults. This feature is currently being implemented and
will be released in a future version of Cpipe.
Internal variant database
A common diagnostic strategy for rare diseases is to fil-
ter out variants that are observed at a frequency in the
population that is inconsistent with the prevalence of
the disease. High throughput sequencing typically identi-
fies many thousands of variants that are observed in
multiple samples. These variants are often not present in
public population databases either due to them being
population-specific or technical artefacts. Cpipe there-
fore maintains an internal database of all variants ob-
served in all samples that are processed by that specific
instance of Cpipe. The frequency of observations in this
internal database may be used as a criterion for excluding
Fig. 2 Simplified Cpipe analysis steps. Cpipe consists of a number of steps. The core of these are based on the best practice guidelines published
by the Broad Institute, consisting of alignment using BWA mem, duplicate removal using Picard MarkDuplicates, local realignment and base
quality score recalibration using GATK, and variant calling using GATK HaplotypeCaller. To support clinical requirements, many steps are added
including quality control steps (BEDTools coverage and QC summary), additional annotation (Annovar and the Variant Effect Predictor, VEP) and
enhanced reports (Annotated variants, Provenance PDF, QC Excel report and Gap Analysis)
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public databases. The internal database is implemented
using SQLite [16]. SQLite is a fully embedded database
technology that stores all data in a single, stand-alone
file. This simplifies the configuration and installation of
the pipeline by removing the need for an external data-
base server.
The internal variant database accumulates variants
over time as more analyses are run. Therefore, a sample
that is re-analysed by Cpipe at a later date may be
assigned different values for the frequency at which vari-
ants are observed in the internal database. Apart from
this single measure, however, Cpipe is designed so that
entering identical input data always produces identical
analysis results. To ensure complete reproducibility, the
SQLite database file may be archived to capture a snap-
shot of the database prior to each analysis.
Quality control reports
In the diagnostic setting, it is critical to assess which re-
gions of a gene were adequately interrogated by the test,
so that clinicians can determine if additional sequencing
is required to detect a causative variant in that gene. It
is therefore necessary that detailed information aboutsequencing coverage is provided in QC reports. Cpipe
supports this requirement by producing three separate
reports: a gene level report, an exon level report and a
detailed base-pair level gap report. These allow a cur-
ator or clinician to rapidly understand, at a high level,
the quality of the sequencing coverage, and then to in-
vestigate in more detail if a particular gene or exon is
of concern.
The scale of clinical operations means that only a
small number of staff may be responsible for running
many simultaneous analyses. It is therefore important
that as many essential quality checks as possible are au-
tomated. Cpipe uses the Bpipe ‘check’ feature to support
automated checks in the pipeline. Failure of these checks
results in an automated email notification to the pipeline
operator with an attached document describing the
failure. These include: (1) failure of a sample if specific
FASTQC measures fail; (2) failure of a sample if the
overall median coverage falls below a configurable
threshold; (3) failure if the median fragment size of the
sequenced reads falls outside a user configurable range;
(4) failure of a sample if the rate of PCR duplicates is
greater than a user configurable threshold; (5) failure of
a sample if a bioinformatic check of the sex of the
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ple in the inputs to the pipeline.
Prioritisation, categorisation and filtering of variants
One of the most significant challenges in bringing high
throughput sequencing into routine clinical care is that
of scaling the difficult and highly manual job of curation,
classification/interpretation and reporting of variants.
This task frequently presents a ‘bottleneck’ in diagnostic
workflows, limited by the number of trained staff with
the required expertise to evaluate the variants and report
the results. To address this, Cpipe implements a filtering
and prioritisation system designed to automatically
highlight the results most likely to be relevant for the
majority of cases. This system was designed in close col-
laboration with clinicians in the Melbourne Genomics
Health Alliance and aims to reflect the usual approach
taken by a curator when first faced with a variant list
from a given patient. The approach consists of two strat-
egies that dramatically reduce the number of variants to
be clinically considered in the first instance (Fig. 3).
The first is a specifically defined system, the Variant
Priority Index that combines a range of factors to place
variants into four distinct tiers (Fig. 3a). The tiers are or-
dered according to measures of rarity, conservation and
truncating effect on the transcript protein. Tiers one,
two and three are subsets of each other. Tier one (VPI
1) corresponds to ‘rare’ in-frame indels or missense vari-
ants with frequency less than 0.01 in EVS [17], 1000GFig. 3 Variant and Gene Priority Indexes. Curation of variants is aided by a
of the variant including frequency in population databases, conservation sc
strength of association of the gene to the phenotype under consideration[18] and ExAC [19]. Variants are elevated to tier two
(VPI 2) ‘very rare or novel’ if their frequency in these
population databases is less than 0.0005. Likewise, tier
two variants are promoted to tier three (VPI 3) if they
are also ‘highly conserved’ (Condel >0.07) [20] as well as
‘very rare or novel’. VPI 4 is reserved for the highest pri-
ority variants including frameshift, truncating and splice
site variants. The tiers provide an intuitive first pass pri-
oritisation of variants, making it easier for curators to
quickly see potentially important variants and therefore
helping to manage their workload. Variants that do not
meet the criteria for at least VPI 1, are hidden in the re-
sult set.
The second strategy is a prioritisation of genes into
categories based on a-priori likelihoods for being causal
to the specific patient (Fig. 3b). The Gene Prioritisation
Index starts with all genes in the analysis profile target
region (GPI 1), then narrows to genes that are com-
monly known to be causal for the disease or patient
group (GPI 2), and finally narrows again to a set of
custom genes that may be prioritised by the patient’s
clinician based on individual considerations, such as
phenotype, using either in-silico programs (GPI 3) or
their own clinical acumen (GPI 4).
Output results
The final result of the bioinformatics pipeline is a
spreadsheet containing filtered and annotated variants.
The format of this spreadsheet is designed to aid rapidprioritisation system that ranks variants according to (a) characteristics
ores and the predicted impact on protein product, and (b) the
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previously described Variant Priority Index and Gene
Priority Index such that the most promising variants are
sorted to the top of the spreadsheet.
As an adjunct, a set of files in CSV format is produced
that contain identical information to the spreadsheet,
but which are formatted in such a way as to facilitate in-
put into an LOVD3 [21] compatible database. Exploiting
this capability, the Melbourne Genomics Health Alliance
has developed an enhanced version of LOVD3 (MG-
LOVD) that includes functionality to greatly facilitate
the curation, classification/interpretation and reporting
process (paper in preparation).
Regression tests
All aspects of the technology surrounding clinical gen-
omics are quickly evolving. It is thus essential that soft-
ware pipelines are readily adaptable to new changes.
However such changes must be validated to ensure they
do not affect the clinical results of the pipeline in an
unexpected way. To assist with this, Cpipe includes a
set of automated software regression tests, which oper-
ate as a ‘self-test module’. The first of these tests ana-
lyses sequence data from chromosome 22 of the Coriell
sample NA12878 [22], and then compares results to a
set of predefined high confidence calls published by
Illumina as part of the Platinum Genomes Project [23].
The test fails if insufficient sensitivity is observed. A
second test simulates variants in data from the same
sample using a simulation tool, Bamsurgeon [24], to
test detection and correct annotation of a range of vari-
ants that would typically be treated as clinically signifi-
cant. Finally, the self-test module performs a number of
additional software regression tests to confirm that the
automated quality checks in the pipeline are function-
ing correctly. These tests do not substitute for the full
and rigorous validation required by accreditation agen-
cies. However, they nonetheless play a vital role in
supporting ongoing development by providing immedi-
ate feedback about the impact of any change on the
pipeline.
Results and discussion
We have implemented Cpipe, an exome analysis pipeline
designed specifically for the needs of clinical users.
Cpipe has been developed through an extensive process
of consultation between many different stakeholders
involved in the Melbourne Genomics Health Alliance
including bioinformaticians, IT specialists, sequencing
laboratories, diagnostic users, and genetic and specialist
clinicians. Cpipe takes raw sequence data and patient
specific analysis profiles and performs variant calling
and prioritisation. In addition it provides multiple re-
ports including QC reports and provenance files. Resultsof Cpipe can also be imported into public variant data-
bases (Fig. 4).
Evaluation in production setting
After development, Cpipe was deployed in an oper-
ational diagnostic setting and to date has been used to
analyse 168 exomes as part of the Melbourne Genomics
Health Alliance demonstration project. This project was
designed to prototype the deployment of exome sequen-
cing as a clinical diagnostic test within a health system
in the states of Victoria and Tasmania in Australia. The
samples were chosen from five diverse disease cohorts
to evaluate different diagnostic applications. Results
from Cpipe were imported into an instance of MG-
LOVD database that was presented to curators and clini-
cians to facilitate the identification of causal variants for
each patient. While the specific diagnostic outcomes for
the Melbourne Genomics Health Alliance demonstration
project will be reported elsewhere, we found that using
the outputs generated by Cpipe, the diagnostic rate for a
broad range of Mendelian adult and childhood condi-
tions compares favourably to well established clinical
genomics projects that claim diagnostic rates in the
range of 25 % to 35 % [25, 26].
Samples were sequenced using Illumina HiSeq 2500
instruments after capture by the Nextera V1.2 exome
capture kit. Sequencing was performed at two laborator-
ies, the Australian Genome Research Facility and the
Centre for Translational Pathology, The University of
Melbourne. Samples were sequenced and processed in
batches of 12, yielding approximately 50 million reads
per sample. Median coverage depth for each sample var-
ied between 75 and 254 (median = 129, n = 168). To
process the samples, Cpipe was deployed on a 32 core
system with 1TB of RAM and a high performance GPFS
storage system. Typically, Cpipe processed a batch of 12
samples in 24 h. On average each sample required a
peak of 21 GB of space, however Cpipe automatically re-
claims space used by intermediate files so that the mean
space consumed per sample was 15 GB. While the pro-
cessing time for an example batch of 12 samples was 24
h 28 min, the total computation time accumulated by all
processing stages for 12 samples was approximately 187
h. Bpipe’s automatic parallelisation features thus allowed
significant reduction in the processing time.
Variant prioritisation and filtering
The combination of the Variant Prioritisation Index,
Gene Prioritisation Index and filtering significantly re-
duces the number of variants prioritised for curation.
For example, a small gene panel of 55 candidate genes
yielded only two variants per sample to be curated on
average (in the range of 0 to 6, n = 31). For larger panels
containing up to 3,000 genes, there were on average 115
Fig. 4 Overview of Cpipe workflow Cpipe accepts a flexible arrangement of exome or targeted capture samples. Each sample is assigned an
Analysis Profile that determines the particular settings and gene list to analyse for that sample. Provenance and QC reports are produced as Excel
and PDF files, while variant calls are delivered as both an Excel spreadsheet and a CSV file that is importable to LOVD3. In addition to allele
frequencies from population databases, allele frequencies are also annotated from an internal embedded database that automatically tracks local
population variants and sequencing artefacts
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range of 76 to 183, n = 37). This was reduced to an
average of 1.45 variants per patient (in the range of 0 to
6, n = 35) when the treating clinician defined a group
of genes as Gene Priority Index 4. The average number
of genes in Gene Priority Index 4 was 21 (in the range
of 1 to 100, n = 35).
In the operational setting where the Melbourne
Genomics Health Alliance has processed 168 samples,
we observe that 89 % of all non-synonymous coding
variants are removed by filtering on allele frequency in
the 1000 genomes project [18] and the Exome Sequencing
Project [17]. As described, Cpipe also uses an internal
variant database to filter out variants that are observed in
multiple samples and that belong to different disease co-
horts. A further 39 % of the remaining variants were able
to be removed by filtering using the internal variant data-
base. This demonstrates that even after filtering using
public databases, maintaining a local variant database is
still important for removing common private population
variants and artefacts introduced by sequencing or bio-
informatic steps.
An example of the Cpipe output in Excel format is in-
cluded as an additional file (see Additional file 1).
Variant calling performance
To check the variant calling performance achieved by
Cpipe using the default GATK based tool set described
earlier, reads from the 1000 Genomes sample NA12878were analysed. This sample was sequenced to a median
coverage depth of 91X as part of the Melbourne Genom-
ics Health Alliance demonstration project. The resulting
variant calls were compared to a set of high confidence
calls obtained from the Illumina Platinum Genomes Pro-
ject (Version 7.0) [23]. For regions in the exome target
Cpipe achieved 90.2 % sensitivity to SNVs in the high
confidence set with a false discovery rate (FDR) of 9 %.
The FDR is calculated by assuming that every Cpipe
variant call that is not found in the high confidence set
is a false positive. This is likely to overestimate of the
false discovery rate, as it is probable that Cpipe detected
some true variants that are not in the high confidence
Platinum Genomes set. After filtering the high confi-
dence calls to include only regions where our sample
had greater than 15× coverage, sensitivity increased to
95.7 %. These rates are indicative of the default variant
calling performance achieved by Cpipe. However we em-
phasise that Cpipe is a framework designed specifically
to allow users to customise the individual tools to suit
their needs. Thus different variant calling options, or an
entirely different variant calling tool can be easily
substituted to modify performance to the needs of a par-
ticular application.
QC reports
We analysed the healthy control sample NA12878 for a
gene panel previously published for diagnosis of cardio-
myopathy patients [27] to generate examples of the QC
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Additional file 2) provides a high level view that al-
lows a curator to quickly assess whether coverage is
adequate over the genes of interest with a color-coded
system. Two out of 20 genes from the panel were iden-
tified as having potentially unsatisfactory coverage. The
exon-level report details which exons within these
genes of interest have insufficient coverage. In this case,
12 exons were reported as being only partially covered,
representing 32 % of the total exons in poor quality
genes (see Additional file 3). The gap report allows
exact identification of all regions having coverage below
a fixed, user-configurable threshold (see Additional file 3).
Thus a curator can discover at sub-exon level which
regions have poor coverage and potentially suggest
follow-up sequencing to address these specific gen-
omic positions. Our test sample contained 55 distinct
regions having poor coverage. These regions accounted
for 1.3 kb of sequence in total (3.8 % of the gene panel
target regions).
The built in QC reporting features provided by Cpipe
allow clinical users to quickly and easily ascertain if
sequencing has achieved sufficient quality to diagnose a
patient. A feature of the Cpipe framework is that it is
very straightforward to customise these reports and to
add new reports.
Conclusions
We have presented Cpipe, a new exome and targeted
sequencing analysis pipeline that is designed specifically
to support clinical needs. As clinical implementation of
sequencing data becomes widespread there is a need
for a freely available analysis platform that can be
shared between clinical laboratories. Cpipe is currently
in routine use at three separate institutions in
Melbourne and is undergoing accreditation for diagnos-
tic use. These organisations are actively maintaining the
common pipeline. Cpipe is made available by the
Melbourne Genomics Health Alliance under the open
source GPLv3 license, allowing full and free use of the
pipeline for both commercial and non-commercial pur-
poses. By adopting Cpipe as their clinical sequencing
pipeline framework, other members of the clinical se-
quencing community can benefit, not just from a pipe-
line that already contains many needed features, but




Project Home Page: http://cpipeline.org
Operating system(s): Linux/Unix
Programming language: Mixed: Java, Groovy, Python,
BashOther requirements: Reference data, Java 1.7+, Perl
5.10+, Python 2.7+
License: GPLv3
Any restrictions to use by non-academics: Two pro-
grams (GATK and Annovar) that are required for the
full features of the software may require a license for
commercial use. Cpipe can work with a reduced feature
set without these tools.
Additional files
Additional file 1: An example of the final report in Excel format
produced by Cpipe. This example is produced from sequencing reads
for 1000 Genomes sample NA12878 over a panel of genes related to
epilepsy.
Additional file 2: An example of the sample summary PDF
produced by Cpipe for high level quality control purposes. This
example is produced from sequencing reads for 1000 Genomes sample
NA12878 over a panel of genes related to cardiomyopathy.
Additional file 3: An example of the detailed quality control
spreadsheet containing coverage gaps and exon level coverage
details for each gene in the diagnostic target region of the analysis
profile. This example is produced from sequencing reads for 1000
Genomes sample NA12878 over a panel of genes related to
cardiomyopathy.
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